Granel B
Service de médecine interne, hôpital de La Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France.
Rev Med Interne. 2004 Apr;25(4):299-302. doi: 10.1016/j.revmed.2004.01.003.
B-type natriuretic peptide is a neurohormone synthesized in the cardiac ventricles upon ventricular pressure overload and ventricular dilatation. This peptide with many favourable physiological properties has emerged as important candidate for development of diagnosis and prognostic tools and therapeutic agents in cardiovascular disease.
Literature published until now shows the interest to measure B-type natriuretic peptide in the diagnosis of ventricular dysfunction or congestive heart failure. B-type natriuretic peptide is also a prognostic marker in patients with congestive heart failure and acute coronary syndrome. It could even help to guide patient treatment management. It is easily and rapidly measured at a reasonable cost. In general, a level less than 50 ng/l has a strong negative predictive value for congestive heart failure.
B-type natriuretic peptide is available in daily clinical practice. Future interest has focused on development of drugs that modulate its effects in treatment of decompensated congestive heart failure. Studies are in progress and first results seem to be promising.
B型利钠肽是一种在心室压力超负荷和心室扩张时于心室中合成的神经激素。这种具有多种有利生理特性的肽已成为开发心血管疾病诊断和预后工具及治疗药物的重要候选物。
迄今为止发表的文献表明,人们对在心室功能障碍或充血性心力衰竭的诊断中测量B型利钠肽很感兴趣。B型利钠肽也是充血性心力衰竭和急性冠状动脉综合征患者的预后标志物。它甚至有助于指导患者的治疗管理。它易于快速测量,成本合理。一般来说,低于50 ng/l的水平对充血性心力衰竭具有很强的阴性预测价值。
B型利钠肽已应用于日常临床实践。未来的研究重点是开发在失代偿性充血性心力衰竭治疗中调节其作用的药物。相关研究正在进行中,初步结果似乎很有前景。